Respiratory syncytial virus: prospects for new and emerging therapeutics

Area of Science:

• Virology
• Infectious Diseases
• Immunology

Background:

• Respiratory syncytial virus (RSV) is a primary cause of lower respiratory tract infections (LRTI) in vulnerable populations, including infants, the elderly, and immunocompromised individuals.
• Despite decades of research, an effective RSV vaccine remains unavailable, and current treatments like palivizumab and ribavirin have limited efficacy, highlighting a critical unmet medical need.
• Supportive care, such as hydration and oxygenation, is the mainstay for managing RSV LRTI.

Purpose of the Study:

• To review current antiviral drugs and monoclonal antibodies (mAbs) in clinical development for RSV prevention and treatment.
• To discuss emerging therapeutic strategies targeting RSV.
• To explore future directions in combating RSV infections.

Main Methods:

• Review of clinical trial data for antiviral drugs and mAbs targeting RSV.
• Analysis of emerging research on novel therapeutic targets beyond the RSV fusion protein.
• Discussion of potential combination antiviral therapies.

Main Results:

• Several new antiviral drugs and mAbs targeting RSV have demonstrated clinical promise in recent years.
• Novel approaches targeting different RSV viral proteins, in addition to the fusion protein, are showing encouraging results.
• The development of RSV escape mutants necessitates consideration of combination antiviral therapies.

Conclusions:

• New antiviral agents and mAbs offer hope for improved prevention and treatment of RSV infections.
• Targeting diverse viral proteins and exploring combination therapies are crucial for overcoming RSV resistance.
• The landscape of RSV therapeutics is evolving, with potential new options on the horizon.